DE69831971D1 - Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer - Google Patents

Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer

Info

Publication number
DE69831971D1
DE69831971D1 DE69831971T DE69831971T DE69831971D1 DE 69831971 D1 DE69831971 D1 DE 69831971D1 DE 69831971 T DE69831971 T DE 69831971T DE 69831971 T DE69831971 T DE 69831971T DE 69831971 D1 DE69831971 D1 DE 69831971D1
Authority
DE
Germany
Prior art keywords
alzheimer
suppression
changes associated
beta amyloid
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69831971T
Other languages
English (en)
Other versions
DE69831971T2 (de
Inventor
L Weiner
J Selkoe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharma International Ltd
Original Assignee
Neuralab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26747618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69831971(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuralab Ltd filed Critical Neuralab Ltd
Publication of DE69831971D1 publication Critical patent/DE69831971D1/de
Application granted granted Critical
Publication of DE69831971T2 publication Critical patent/DE69831971T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Engine Equipment That Uses Special Cycles (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69831971T 1997-12-03 1998-12-03 Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer Expired - Lifetime DE69831971T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6721997P 1997-12-03 1997-12-03
US67219P 1997-12-03
US7969798P 1998-03-27 1998-03-27
US79697P 1998-03-27
PCT/US1998/025694 WO1999027949A1 (en) 1997-12-03 1998-12-03 METHOD OF SUPPRESSING β-AMYLOID-RELATED CHANGES IN ALZHEIMER'S DISEASE

Publications (2)

Publication Number Publication Date
DE69831971D1 true DE69831971D1 (de) 2006-03-02
DE69831971T2 DE69831971T2 (de) 2006-07-06

Family

ID=26747618

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1033998T Pending DE1033998T1 (de) 1997-12-03 1998-12-03 Methode zur unterdrückung von beta-amyloid-verwandten veränderungen in alzheimer
DE69831971T Expired - Lifetime DE69831971T2 (de) 1997-12-03 1998-12-03 Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE1033998T Pending DE1033998T1 (de) 1997-12-03 1998-12-03 Methode zur unterdrückung von beta-amyloid-verwandten veränderungen in alzheimer

Country Status (8)

Country Link
EP (1) EP1033998B1 (de)
JP (2) JP2002511385A (de)
AT (1) ATE306931T1 (de)
AU (1) AU742970C (de)
CA (1) CA2312475C (de)
DE (2) DE1033998T1 (de)
ES (1) ES2253839T3 (de)
WO (1) WO1999027949A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1072897A (en) 1995-12-12 1997-07-03 Karolinska Innovations Ab Peptide binding the klvff-sequence of amyloid beta
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
DE1033998T1 (de) * 1997-12-03 2001-05-23 Brigham And Women's Hospital, Boston Methode zur unterdrückung von beta-amyloid-verwandten veränderungen in alzheimer
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
PT1284998E (pt) * 2000-05-22 2005-06-30 Univ New York Eptideos imunogenicos sinteticos mas nao-amiloidogenicos homologos a beta-amiloides, destinados a induzir uma reaccao imunitaria contra os beta-amiloides e os depositos amiloides
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
CA2466841A1 (en) 2001-11-21 2003-06-05 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
NZ537688A (en) 2002-07-19 2007-01-26 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays for treating and/or attenuating Alzheimer's disease
WO2004056318A2 (en) 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
DE602007011415D1 (de) 2006-03-23 2011-02-03 Bioartic Neuroscience Ab Verbesserte protofibrilselektive antikörper und deren verwendung
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP5889529B2 (ja) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
EP2603524A1 (de) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta-bindende proteine
US8906382B2 (en) 2011-07-19 2014-12-09 New York University Method for treating amyloid disease
US9926353B2 (en) 2011-07-19 2018-03-27 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
US20150290158A1 (en) * 2012-11-09 2015-10-15 Elliott C. Lasser X-ray contrast media compositions and methods of using the same to treat, reduce or delay the onset of cns inflammation and inflammation associated conditions
PL3166970T3 (pl) 2014-07-10 2021-09-13 Bioarctic Ab Ulepszone przeciwciała wiążące protofibryle a-beta

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) * 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
CA2081482C (en) * 1990-04-27 2000-11-21 Ellis L. Kline Method and composition for treatment of central nervous system disease states associated with abnormal amyloid beta protein molecular organization
ATE202940T1 (de) * 1994-05-25 2001-07-15 John Mcmichael Mittel und methoden zur behandlung von plaque- krankheiten
WO1996039176A1 (en) * 1995-06-05 1996-12-12 Brigham & Women's Hospital USE OF ORAL TOLERANCE TO SUPPRESS BOTH Th1 AND Th2 IMMUNE RESPONSES AND TO SUPPRESS ANTIBODY PRODUCTION
WO1997018855A1 (en) * 1995-11-21 1997-05-29 Eduard Naumovich Lerner Device for enhanced delivery of biologically active substances and compounds in an organism
ZA97452B (en) * 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
JPH09208485A (ja) * 1996-01-31 1997-08-12 Teijin Ltd ペプチド・蛋白質性薬物の水難溶性組成物
DE1033998T1 (de) * 1997-12-03 2001-05-23 Brigham And Women's Hospital, Boston Methode zur unterdrückung von beta-amyloid-verwandten veränderungen in alzheimer

Also Published As

Publication number Publication date
ATE306931T1 (de) 2005-11-15
WO1999027949A9 (en) 1999-09-10
JP2002511385A (ja) 2002-04-16
ES2253839T3 (es) 2006-06-01
WO1999027949A1 (en) 1999-06-10
EP1033998A4 (de) 2003-06-04
AU742970C (en) 2003-03-20
DE1033998T1 (de) 2001-05-23
CA2312475A1 (en) 1999-06-10
JP2010215627A (ja) 2010-09-30
CA2312475C (en) 2010-08-03
EP1033998B1 (de) 2005-10-19
AU742970B2 (en) 2002-01-17
DE69831971T2 (de) 2006-07-06
EP1033998A1 (de) 2000-09-13
AU1709999A (en) 1999-06-16

Similar Documents

Publication Publication Date Title
DE69831971D1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
EP0552256A4 (de)
DE69331409D1 (de) Oral 1alpha-hydroxyprevitamin d
EE05492B1 (et) Farmatseutilised kompositsioonid, nendega seotud meetodid ja nende kasutamine amloidogeensete haiguste korral
NO20092874L (no) Forhindring og behandling av amyloidogen sykdom
WO1994027589A3 (en) Antidepressant dosage form
ATE117548T1 (de) Pharmazeutische zubereitungen zur verhütung von arzneimitteltoleranz.
CY1105707T1 (el) Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου
IL138665A0 (en) Peptide factor
SE9703191D0 (sv) Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
IT1222395B (it) Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
DK0629400T3 (da) Idebenon-holdige præparater til behandling af Alzheimer's syge
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
DE69314586D1 (de) Arzneimittelzusammensetzung enthaltend TCF-II
SE8800461D0 (sv) Farmaceutisk komposition
MY112888A (en) Use of bradykinin antagonists for the preparation of medicaments for the treatment of virus diseases.
IL101540A0 (en) Method and composition for the treatment of herpes related disorders
DE59410137D1 (de) Neue pharmazeutische zubereitungen zur oralen verabreichung enthaltend cyclosporin
ES2173550T3 (es) Uso de olanzapina para la fabricacion de un medicamento para la neuroproteccion.
LV5179A3 (lv) Preparats "etoksidins" teju kunga un zarnu slimibu profilaksei un arstesanai
IT1254191B (it) Composizioni farmaceutiche stabili per la somministrazione orale di calcitonina

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: ELAN PHARMA INTERNATIONAL LTD., ATHLONE, WESTM, IE

8365 Fully valid after opposition proceedings